bluuebunny/crossref_metadata_2025_split huggingface dataset:
Determinants of tumor treating field usage in patients with primary glioblastoma: A single institutional experience
Authors: Ballo Matthew T , Qualls Kaitlin W , Michael L Madison , Sorenson Jeffrey M , Baughman Brandon , Karri-Wellikoff Saradasri , Pandey Manjari 
Published: September 2022

Abstract

Background
Determinates of tumor treating fields (TTFields) usage in patients receiving combined modality therapy for primary IDH wild-type glioblastoma are currently unknown.

Methods
Ninety-one patients underwent maximal debulking surgical resection, completed external beam radiotherapy with concurrent Temozolomide (TMZ), and initiated adjuvant TMZ with or without TTFields. We performed a retrospective analysis of patient, tumor, and treatment-related factors that affected TTFields usage.

Results
We identified three TTFields usage subgroups: 32 patients that declined TTFields, 40 patients that started, but had monthly compliance of less than 75% or used it for less than 2 months, and 19 patients who used TTFields for 2 or more months and maintained average monthly compliance greater than 75%. With 26.5 months median follow-up for surviving patients, the 1- and 3-year actuarial overall survival for all patients was 80% and 18%, respectively. On multivariate analysis TTFields use (P = .03), extent of surgical resection (P = 0.02), and MGMT methylation status (P = .01) were significantly associated with overall survival. TTFields usage was explored as a continuous variable and higher average usage was associated with longer overall survival (P = .03). There was no relationship between patient, tumor, or treatment-related factors and a patient’s decision to use TTFields.

Conclusions
No subgroup of patients was more or less likely to initiate TTFields therapy and no subgroup was more or less likely to use TTFields as prescribed. The degree of TTFields compliance may be associated with improved survival independent of other factors.
Soft, biocompatible materials and skin-like electronics as wearable devices: an interview with John A. Rogers
Authors: Song By Enming 
Published: September 2022

Abstract
Recent advances in active materials, micro-fabrication techniques, ultra-miniaturized design approaches and hybrid device layouts form the foundations for emerging classes of unusual systems that can capture physiological signals from the human body in a physically imperceptible fashion at nearly any anatomical location, external on the skin or internal on vital organ systems. Of particular interest with these technologies are their thin geometries, flexible/stretchable physical properties and unique form factors, to enable conformal and gentle contacts with soft, curved and dynamic surfaces of living tissues. Commercial embodiments of skin-integrated devices with clinical-grade monitoring capabilities are just now becoming widely available not only in developed countries but also in the most resource-constrained areas of the globe. A specific example is in skin-like—sometimes referred to as ‘epidermal’—wireless electronics for continuous monitoring of essential markers of physiological health status, with accuracy and reliability comparable to that of expensive, wired-based systems currently used with patients in intensive care units, but cost-effectively and applicable in any setting—in hospitals, health clinics, work environments or in the home. These technologies have the potential to revolutionize diagnostic and therapeutic approaches for the care of patients.
NSR spoke to one of the scientific leaders in this field—a 2009 MacArthur Fellow, the winner of the 2022 US National Academy of Sciences James Prize in Science and Technology Integration and one of the few individuals in history to be elected to all three US National Academies, namely the National Academy of Engineering, the National Academy of Science and the National Academy of Medicine, Professor John A. Rogers, the Director of the Querrey-Simpson Institute of Bioelectronics at Northwestern University on the recent advancements and the prospects of soft, biocompatible electronic systems and skin-like wearable devices.
Standardization of Epidemiological Surveillance of Rheumatic Heart Disease
Authors: Scheel Amy , Miller Kate M , Beaton Andrea , Katzenellenbogen Judith , Parks Tom , Cherian Thomas , Van Beneden Chris A , Cannon Jeffrey W , Moore Hannah C , Bowen Asha C , Carapetis Jonathan R ,   for the Strep A Vaccine Global Consortium (SAVAC) Burden of Disease Working Group
Published: September 2022

Abstract
Rheumatic heart disease (RHD) is a long-term sequela of acute rheumatic fever (ARF), which classically begins after an untreated or undertreated infection caused by Streptococcus pyogenes (Strep A). RHD develops after the heart valves are permanently damaged due to ARF. RHD remains a leading cause of morbidity and mortality in young adults in resource-limited and low- and middle-income countries. This article presents case definitions for latent, suspected, and clinical RHD for persons with and without a history of ARF, and details case classifications, including differentiating between definite or borderline according to the 2012 World Heart Federation echocardiographic diagnostic criteria. This article also covers considerations specific to RHD surveillance methodology, including discussions on echocardiographic screening, where and how to conduct active or passive surveillance (eg, early childhood centers/schools, households, primary healthcare), participant eligibility, and the surveillance population. Additional considerations for RHD surveillance, including implications for secondary prophylaxis and follow-up, RHD registers, community engagement, and the negative impact of surveillance, are addressed. Finally, the core elements of case report forms for RHD, monitoring and audit requirements, quality control and assurance, and the ethics of conducting surveillance are discussed.
Open-Label Placebo for the Treatment of Cancer-Related Fatigue in Patients with Advanced Cancer: A Randomized Controlled Trial
Authors: Yennurajalingam Sriram , Azhar Ahsan , Lu Zhanni , Rodriguez Ashley J , Arechiga Adrienne B , Guerra-Sanchez Maria , Stanton Penny , Andersen Clark R , Urbauer Diana L , Bruera Eduardo 
Published: September 2022

Abstract

Background
The purpose of this study was to determine the effects of an open-labeled placebo (OLP) compared to a waitlist control (WL) in reducing cancer-related fatigue (CRF) in patients with advanced cancer using Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F).

Materials and Methods
In this randomized controlled trial, patients with fatigue ≥4/10 on Edmonton Symptom Assessment Scale (ESAS) were randomized to OLP one tablet twice a day or WL for 7 days. On day 8, patients of both arms received a placebo for 3 weeks. Changes in FACIT-F from baseline to day 8 (primary outcome) and at day 29, were assessed. Secondary outcomes included FACT-G, Multidimensional Fatigue Symptom Inventory-SF, Fatigue cluster (defined as a composite of ESAS fatigue, pain, and depression), Center for epidemiologic studies-depression, Godin leisure-time physical activity questionnaire, and global symptom evaluation.

Results
A total of 84/90 (93%) patients were evaluable. The mean (SD) FACIT-F change at day 8 was 6.6 (7.6) after OLP, vs. 2.1 (9.4) after WL (P = .016). On days 15 and 29, when all patients received OLP, there was a significant improvement in CRF and no difference between arms. There was also a significant improvement in ESAS fatigue, and fatigue cluster score in the OLP arm on day 8 of the study (0.029, and 0.044, respectively). There were no significant differences in other secondary outcomes and adverse events between groups.

Conclusions
Open-labeled placebo was efficacious in reducing CRF and fatigue clusters in fatigued advanced cancer patients at the end of 1 week. The improvement in fatigue was maintained for 4 weeks. Further studies are needed.
On Powers BSAs
Authors: Friend Toby 
Published: September 2022

AbstractCan the desire for efficiently systematised theories in science be explained from within a powers metaphysics? It is plausible that the traditional ‘Powers Theory of Laws’, endorsed by many friends of powers, does not alone provide such an explanation. This has led a number of recent authors to argue that a ‘Powers Best System Account’ of laws would be a preferable alternative. This account borrows a method for determining laws from the Humean and applies it to a reality of powers. Here I claim, to the contrary, that this account is both internally unworkable and, anyway, completely undermotivated when compared with the traditional view. Apart from some brief suggestions for alternative accounts, I’ll conclude that the powers theorist still has their work cut out to explain systematising in science.
Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis
Authors: Kearsley-Fleet Lianne , Baildam Eileen , Beresford Michael W , Douglas Sharon , Foster Helen E , Southwood Taunton R , Hyrich Kimme L , Ciurtin Coziana 
Published: September 2022

Abstract

Objectives
Clinicians concerned about long-term safety of biologics in JIA may consider tapering or stopping treatment once remission is achieved despite uncertainty in maintaining drug-free remission. This analysis aims to (i) calculate how many patients with JIA stop biologics for remission, (ii) calculate how many later re-start therapy and after how long, and (iii) identify factors associated with re-starting biologics.

Methods
Patients starting biologics between 1 January 2010 and 7 September 2021 in the UK JIA Biologics Register were included. Patients stopping biologics for physician-reported remission, those re-starting biologics and factors associated with re-starting, were identified. Multiple imputation accounted for missing data.

Results
Of 1451 patients with median follow-up of 2.7 years (IQR 1.4, 4.0), 269 (19%) stopped biologics for remission after a median of 2.2 years (IQR 1.7, 3.0). Of those with follow-up data (N = 220), 118 (54%) later re-started therapy after a median of 4.7 months, with 84% re-starting the same biologic. Patients on any-line tocilizumab (prior to stopping) were less likely to re-start biologics (vs etanercept; odds ratio [OR] 0.3; 95% CI: 0.2, 0.7), while those with a longer disease duration prior to biologics (OR 1.1 per year increase; 95% CI: 1.0, 1.2) or prior uveitis were more likely to re-start biologics (OR 2.5; 95% CI: 1.3, 4.9).

Conclusions
This analysis identified factors associated with successful cessation of biologics for remission in JIA as absence of uveitis, prior treatment with tocilizumab and starting biologics earlier in the disease course. Further research is needed to guide clinical recommendations.
Activation of the left medial temporal gyrus and adjacent brain areas during affective theory of mind processing correlates with trait schizotypy in a nonclinical population
Authors: Vucurovic Ksenija , Raucher-Chéné Delphine , Obert Alexandre , Gobin Pamela , Henry Audrey , Barrière Sarah , Traykova Martina , Gierski Fabien , Portefaix Christophe , Caillies Stéphanie , Kaladjian Arthur 
Published: September 2022

Abstract
Schizophrenia, a severe psychiatric disorder, is associated with abnormal brain activation during theory of mind (ToM) processing. Researchers recently suggested that there is a continuum running from subclinical schizotypal personality traits to fully expressed schizophrenia symptoms. Nevertheless, it remains unclear whether schizotypal personality traits in a nonclinical population are associated with atypical brain activation during ToM tasks. Our aim was to investigate correlations between fMRI brain activation during affective ToM (ToMA) and cognitive ToM (ToMC) tasks and scores on the Schizotypal Personality Questionnaire (SPQ) and the Basic Empathy Scale in 39 healthy individuals. The total SPQ score positively correlated with brain activation during ToMA processing in clusters extending from the left medial temporal gyrus (MTG), lingual gyrus and fusiform gyrus to the parahippocampal gyrus (Brodmann area: 19). During ToMA processing, the right inferior occipital gyrus, right MTG, precuneus and posterior cingulate cortex negatively correlated with the emotional disconnection subscore and the total score of self-reported empathy. These posterior brain regions are known to be involved in memory and language, as well as in creative reasoning, in nonclinical individuals. Our findings highlight changes in brain processing associated with trait schizotypy in nonclinical individuals during ToMA but not ToMC processing.
NDR1/HIN1-Like Protein 13 Interacts with Symbiotic Receptor Kinases and Regulates Nodulation in Lotus japonicus
Authors: Yamazaki Akihiro , Battenberg Kai , Shimoda Yoshikazu , Hayashi Makoto 
Published: September 2022

Lysin-motif receptor-like kinases (LysM-RLKs) are involved in the recognition of microbe-associated molecular patterns to initiate pattern-triggered immunity (PTI). LysM-RLKs are also required for recognition of microbe-derived symbiotic signal molecules upon establishing mutualistic interactions between plants and microsymbionts. A LysM-RLK CHITIN ELICITOR RECEPTOR KINASE1 (CERK1) plays central roles both in chitin-mediated PTI and in arbuscular mycorrhizal symbiosis, suggesting the overlap between immunity and symbiosis, at least in the signal perception and the activation of downstream signal cascades. In this study, we screened for the interacting proteins of Nod factor Receptor1 (NFR1), a CERK1 homolog in the model legume Lotus japonicus, and obtained a protein orthologous to NONRACE-SPECIFIC DISEASE RESISTANCE1/HARPIN-INDUCED1-LIKE13 (NHL13), a protein involved in the activation of innate immunity in Arabidopsis thaliana, which we named LjNHL13a. LjNHL13a interacted with NFR1 and with the symbiosis receptor kinase SymRK. LjNHL13a also displayed positive effects in nodulation. Our results suggest that NHL13 plays a role both in plant immunity and symbiosis, possibly where they overlap. [Formula: see text] Copyright © 2022 The Author(s). This is an open access article distributed under the CC BY-NC-ND 4.0 International license .
Tumor Volume Predicts for Pathologic Complete Response in Rectal Cancer Patients Treated With Neoadjuvant Chemoradiation
Authors: Yang Fan , Hill Jordan , Abraham Aswin , Ghosh Sunita , Steed Tanner , Kurtz Clay , Joseph Kurian , Yun Jihyun , Warkentin Brad , Thai JoAnn , Nijjar Tirath , Severin Diane , Tankel Keith , Fairchild Alysa , Usmani Nawaid 
Published: September 2022

Objectives:
Nonoperative management (NOM) of locally advanced rectal cancer is an emerging approach allowing patients to preserve their anal sphincter. Identifying clinical factors associated with pathologic complete response (pCR) is essential for physicians and patients considering NOM.

Materials and Methods:
In total, 412 locally advanced rectal cancer patients were included in this retrospective analysis. Tumor volumes were derived from pretreatment MRI. Clinical parameters such as tumor volume, stage, and location were analyzed by univariate and multivariate analysis, against pCR. A receiver operator characteristic curve was generated to identify a tumor volume cut-off with the highest clinically relevant Youden index for predicting pCR.

Results:
Seventy-five of 412 patients (18%) achieved pCR. A tumor volume threshold of 37.3 cm3 was identified as predictive for pCR. On regression analysis, a tumor volume >37.3 cm3 was associated with a greater than 78% probability of not achieving pCR. On multivariate analysis, a GTV <37.3 cm3 [odds ratio (OR)=3.7, P<0.0001] was significantly associated with an increased pCR rate, whereas tumor length > 4.85 cm was associated with pCR on univariate (OR=3.03, P<0.01) but not on multivariate analysis (OR=1.45, P=0.261). Other clinical parameters did not impact pCR rates.

Conclusions:
A tumor volume threshold of 37.3 cm3 was identified as predictive for pCR in locally advanced rectal cancer patients receiving neoadjuvant chemoradiation. Tumors above this volume threshold corresponded to a greater than 78% probability of not achieving pCR. This information will be helpful at diagnosis for clinicians who are considering potential candidates for NOM.
Oleander-Associated Keratitis and Uveitis
Authors: Tailor Prashant D. , Farazdaghi Marybeth K. , Patel Sanjay V. , Baratz Keith H. 
Published: September 2022

Purpose:
Oleander is a poisonous plant with extensively documented systemic side effects; however, oleander's ophthalmic side effects have not been detailed in the literature. We report a case of oleander-associated keratitis with subsequent corneal edema and anterior uveitis.

Methods:
This is a case report and review of relevant literature.

Results:
A 58-year-old woman presented with large corneal epithelial defect after being struck in the eye with an oleander leaf. Despite treatment with topical moxifloxacin, she developed severe corneal edema and anterior uveitis. A diagnosis of oleander-associated ocular inflammation with secondary corneal edema was made, given the temporal relationship, and treatment was initiated with topical prednisolone and cyclopentolate. However, the corneal edema and inflammation continued to progress until oral prednisone and topical difluprednate were initiated. Visual acuity, anterior uveitis, and corneal edema significantly improved with aggressive immunomodulation. Follow-up at 1 month confirmed complete recovery of symptoms, corneal edema and anterior uveitis.

Conclusions:
Severe corneal edema and anterior uveitis can be associated with oleander exposure. Aggressive treatment with oral and topical steroids may be required without persistent sequelae at the 5-month follow-up. Ophthalmologists should consider this inflammatory reaction if patients experience ocular exposure to oleander.
Suicide Risk Among Adolescents With ADHD
Authors: Trivedi Chintan , Nandakumar Aiswarya Lakshmi , Yousefzadehfard Yashar , Goriparthi Tulasi S.K. , Chaudhari Gaurav , Vora Darshini , Mansuri Zeeshan , Jain Shailesh 
Published: September 2022

Abstract
Studies have shown an association between attention deficit hyperactivity disorder (ADHD) and suicide; however, it has not been studied from inpatient hospitalization data among adolescents. For this study, data from the National Inpatient Sample data set were used. Based on the diagnosis of ADHD, the patient sample was stratified into two groups. Study group was composed of patients with ADHD, and control group was selected by propensity score matching (1:1), which composed of patients without ADHD. The primary outcome was suicidal ideation/attempt between the groups. Prevalence of SI was 25.1% in patients with ADHD versus 10.3% among patients without ADHD. Prevalence of SA was also very high (8.0% vs 3.9%) among patient with ADHD compared with non-ADHD group. After controlling for covariates, ADHD was a strong predictor of suicidal ideation/attempt with an odds ratio of 2.18. It is important to screen for suicidality in patient with ADHD given the high prevalence of suicidality.
The Accuracy of Computer-Assisted Surgical Planning in Predicting Soft Tissue Responses After Le Fort I Osteotomy: Retrospective Analysis
Authors: Şenyürek S. Aysima , Ajami Sara , Ruggiero Federica , Van de Lande Lara , Caron Cornelia J.J.M. , Schievano Silvia , Dunaway David J. , Padwa Bonnie , Koudstaal Maarten J. , Borghi Alessandro 
Published: September 2022

Purpose:
Mismatch between preoperative planning and surgical outcome in maxillofacial surgery relate to on-table replication of presurgical planning and predictive algorithm inaccuracy: software error was hereby decoupled from planning inaccuracy to assess a commercial software. The hypothesis was that soft tissue prediction error would be minimized if the surgical procedure was replicated precisely as planned and is independent of the extent of bone repositioning.

Materials and Methods:
Cone-beam computed tomography scans of 16 Le Fort I osteotomy patients were collected at Boston Children’s Hospital. Preoperative and postoperative models of bone and soft tissue were constructed and the maxilla repositioning was replicated. Each model was subdivided into 6 regions: mouth, nose, eyes, and cheeks. Soft tissue prediction (performed using Proplan CMF-Materialise) for each patient was compared with the relative postoperative reconstruction and error was determined. P<0.05 was considered significant.

Results:
Le Fort I segment repositioning was replicated within 0.70±0.18 mm. The highest prediction error was found in the mouth (1.49±0.77 mm) followed by the cheeks (0.98±0.34 mm), nose (0.86±0.23 mm), and eyes (0.76±0.32). Prediction error on cheeks correlated significantly with mouth (r=0.63, P< 0.01) and nose (r=0.67, P< 0.01). Mouth prediction error correlated with total advancement (r=0.52, P=0.04).

Conclusions:
ProPlan CMF is a useful outcome prediction tool; however, accuracy decreases with the extent of maxillary advancement even when errors in surgical replication are minimized.
Patient Support Program and Healthcare Resource Utilization in Patients Using Clean Intermittent Catheterization for Bladder Management
Authors: Hasan Shaquib Al , Neal-Herman Levi , Norman Holly S. , Zhao Julie Z. , Carlson Angeline 
Published: September 2022

PURPOSE:
The primary purpose of this study was to evaluate the impact of a patient-centered, chronic care self-management support program of clean intermittent catheterization (CIC) on emergency department (ED) visits and hospitalizations within the first 30 days of starting CIC. Secondary research objectives were to compare reuse of catheters, adherence to healthcare provider–instructed frequency of CIC, and reasons for nonadherence.

DESIGN:
A correlational survey design with 2 respondent groups.

SUBJECTS AND SETTING:
Four hundred forty-five respondents met inclusion criteria for this study; 321 respondents enrolled in an intermittent catheter manufacturer–supported CIC support program, and 124 respondents were not enrolled in a support program (comparison group).

METHODS:
Participants completed a 37-item online questionnaire designed for purposes of this study. Chi-square test was used to assess differences in the proportions of patients with ED visits and overnight hospital admissions comparing respondents enrolled in the patient support program to those not enrolled. Regression analyses were performed to estimate the effect of the CIC support program on ED visit events and on hospital overnight stays.

RESULTS:
Within the first month of CIC initiation, 16.1% and 10.2% of the respondents in the comparison group reported at least 1 ED visit and at least 1 overnight hospital stay, respectively. Respondents participating in the CIC support program experienced a 47% decrease in ED visits (adjusted rate ratio: 0.53; 95% confidence interval: 0.30-0.94, P = .036) and a 77% decrease (adjusted rate ratio: 0.24; 95% confidence interval: 0.10-0.62, P = .002) in hospital overnight stays within the first month of CIC initiation, while controlling for age, sex, education, duration of CIC use, region, health insurance status, and medical conditions necessitating CIC. Respondents in the CIC support program group reported an 8% higher adherence rate with the healthcare provider–instructed frequency of CIC usage compared to the comparison group (88% vs 80%, P = .039).

CONCLUSIONS:
The burden of CIC-related complications within the first month of CIC initiation is significant. A patient-centered, chronic care self-management program for CIC was associated with fewer ED visits and overnight hospital stays during the first month of CIC and improved adherence to prescribed frequency of CIC use.